Proteasomes are not a target for doxorubicin in feline injection-site sarcoma

Journal of Comparative Pathology

Volumn 143, Issue 2-3, 2010, Pages 164-172

  Cerruti, F ^a   Martano, M ^a   Morello, E ^a   Buracco, P ^a   Cascio, P ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Doxorubicin; Feline injection site sarcoma; Proteasome; Proteasome inhibitor

Indexed keywords

CASPASE; CHYMOTRYPSIN; DOXORUBICIN; PROTEASOME;

ANIMAL TISSUE; ARTICLE; CAT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FELINE INJECTION SITE SARCOMA; FEMALE; MALE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SARCOMA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BONE NEOPLASMS; CAT DISEASES; CATS; DOXORUBICIN; FEMALE; HEAD AND NECK NEOPLASMS; INJECTIONS; MALE; PROTEASOME ENDOPEPTIDASE COMPLEX; SARCOMA;

FELIDAE;

EID: 77954954107     PISSN: 00219975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcpa.2010.02.003     Document Type: Article

References (47)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004, 5:417-421.
2. Adams J. The proteasome: a suitable antineoplastic target. Nature Reviews Cancer 2004, 4:349-360.
3. Barber L.G., Sorenmo K.U., Cronin K.L., Shofer F.S. Combined doxorubicin and cyclophosphamide chemotherapy for nonresectable feline fibrosarcoma. Journal of the American Animal Hospital Association 2000, 36:416-421.
4. Bianchi G., Oliva L., Cascio P., Pengo N., Fontana F., et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009, 113:3040-3049.
5. Bregazzi V.S., LaRue S.M., McNiel E., Macy D.W., Dernell W.S., et al. Treatment with a combination of doxorubicin, surgery, and radiation versus surgery and radiation alone for cats with vaccine-associated sarcomas: 25 cases (1995-2000). Journal of the American Veterinary Medical Association 2001, 218:547-550.
6. Cascio P., Call M., Petre B.M., Walz T., Goldberg A.L. Properties of the hybrid form of the 26S proteasome containing both 19S and PA28 complexes. EMBO Journal 2002, 21:2636-2645.
7. Cascio P., Goldberg A.L. Preparation of hybrid (19S-20S-PA28) proteasome complexes and analysis of peptides generated during protein degradation. Methods in Enzymology 2005, 398:336-352.
8. Cascio P., Hilton C., Kisselev A.F., Rock K.L., Goldberg A.L. 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide. EMBO Journal 2001, 20:2357-2366.
9. Cascio P., Oliva L., Cerruti F., Mariani E., Pasqualetto E., et al. Dampening Ab responses using proteasome inhibitors following in-vivo B cell activation. European Journal of Immunology 2008, 38:658-667.
10. Cenci S., Mezghrani A., Cascio P., Bianchi G., Cerruti F., et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO Journal 2006, 25:1104-1113.
11. Cerruti F., Martano M., Petterino C., Bollo E., Morello E., et al. Enhanced expression of interferon-gamma-induced antigen-processing machinery components in a spontaneously occurring cancer. Neoplasia 2007, 9:960-969.
12. Chauhan D., Hideshima T., Mitsiades C., Richardson P., Anderson K.C. Proteasome inhibitor therapy in multiple myeloma. Molecular Cancer Therapeutics 2005, 4:686-692.
13. Cohen M., Wright J.C., Brawner W.R., Smith A.N., Henderson R., et al. Use of surgery and electron beam irradiation, with or without chemotherapy, for treatment of vaccine-associated sarcomas in cats: 78 cases (1996-2000). Journal of the American Veterinary Medical Association 2001, 219:1582-1589.
14. Dang C.V., Kim J.W., Gao P., Yustein J. The interplay between MYC and HIF in cancer. Nature Reviews Cancer 2008, 8:51-56.
15. Figueiredo-Pereira M.E., Chen W.E., Li J., Johdo O. The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome. Journal of Biological Chemistry 1996, 271:16455-16459.
16. Fuchs D., Berges C., Opelz G., Daniel V., Naujokat C. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. Journal of Cellular Biochemistry 2008, 103:270-283.
17. Glotzer M., Murray A.W., Kirschner M.W. Cyclin is degraded by the ubiquitin pathway. Nature 1991, 349:132-138.
18. Goldberg A.L., Cascio P., Saric T., Rock K.L. The importance of the proteasome and subsequent proteolytic steps in the generation of antigenic peptides. Molecular Immunology 2002, 39:147-164.
19. Hanna J., Finley D. A proteasome for all occasions. FEBS Letters 2007, 581:2854-2861.
20. Hendrick M.J., Brooks J.J. Postvaccinal sarcomas in the cat: histology and immunohistochemistry. Veterinary Pathology 1994, 31:126-129.
21. Hendrick M.J., Goldschmidt M.H., Shofer F.S., Wang Y.Y., Somlyo A.P. Postvaccinal sarcomas in the cat: epidemiology and electron probe microanalytical identification of aluminum. Cancer Research 1992, 52:5391-5394.
22. Hendrick M.J., Kass P.H., McGill L.D., Tizard I.R. Postvaccinal sarcomas in cats. Journal of the National Cancer Institute 1994, 86:341-343.
23. Hideshima T., Mitsiades C., Akiyama M., Hayashi T., Chauhan D., et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003, 101:1530-1534.
24. Hong X., Lei L., Glas R. Tumors acquire inhibitor of apoptosis protein (IAP)-mediated apoptosis resistance through altered specificity of cytosolic proteolysis. Journal of Experimental Medicine 2003, 197:1731-1743.
25. Kass P.H., Barnes W.G., Spangler W.L., Chomel B.B., Culbertson M.R. Epidemiologic evidence for a causal relation between vaccination and fibrosarcoma tumorigenesis in cats. Journal of the American Veterinary Medical Association 1993, 203:396-405.
26. Kiyomiya K., Matsuo S., Kurebe M. Mechanism of specific nuclear transport of adriamycin: the mode of nuclear translocation of adriamycin-proteasome complex. Cancer Research 2001, 61:2467-2471.
27. Kiyomiya K., Kurebe M., Nakagawa H., Matsuo S. The role of the proteasome in apoptosis induced by anthracycline anticancer agents. International Journal of Oncology 2002, 20:1205-1209.
28. Kiyomiya K., Satoh J., Horie H., Kurebe M., Nakagawa H., et al. Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome. International Journal of Oncology 2002, 21:1081-1085.
29. Lee C.S., Tee L.Y., Warmke T., Vinjamoori A., Cai A., et al. A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. Journal of Neurochemistry 2004, 91:996-1006.
30. London M.K., Keck B.I., Ramos P.C., Dohmen R.J. Regulatory mechanisms controlling biogenesis of ubiquitin and the proteasome. FEBS Letters 2004, 567:259-264.
31. Lundgren J., Masson P., Mirzaei Z., Young P. Identification and characterization of a Drosophila proteasome regulatory network. Molecular and Cellular Biology 2005, 25:4662-4675.
32. Ma Y., Hendershot L.M. The role of the unfolded protein response in tumour development: friend or foe?. Nature Reviews Cancer 2004, 4:966-977.
33. Martano M., Morello E., Ughetto M., Iussich S., Petterino C., et al. Surgery alone versus surgery and doxorubicin for the treatment of feline injection-site sarcomas: a report on 69 cases. Veterinary Journal 2005, 170:84-90.
34. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nature Reviews Cancer 2007, 7:961-967.
35. McNiel E.A. Vaccine-associated sarcomas in cats: a unique cancer model. Clinical Orthopaedics and Related Research 2001, 382:21-27.
36. Meiners S., Heyken D., Weller A., Ludwig A., Stangl K., et al. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of mammalian proteasomes. Journal of Biological Chemistry 2003, 278:21517-21525.
37. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacological Reviews 2004, 56:185-229.
38. Owen L. TNM Classification of Tumors in Domestic Animals 1980, World Health Organization, Geneva.
39. Pagano M., Tam S.W., Theodoras A.M., Beer-Romero P., Del Sal G., et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995, 269:682-685.
40. Poirier V.J., Thamm D.H., Kurzman I.D., Jeglum K.A., Chun R., et al. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. Journal of Veterinary Internal Medicine 2002, 16:726-731.
41. Santoni de Sio F.R., Cascio P., Zingale A., Gasparini M., Naldini L. Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 2006, 107:4257-4265.
42. Santoni de Sio F.R., Gritti A., Cascio P., Neri M., Sampaolesi M., et al. Lentiviral vector gene transfer is limited by the proteasome at post-entry steps in various types of stem cells. Stem Cells 2008, 26:2142-2152.
43. Seguin B. Feline injection site sarcomas. Veterinary Clinics of North America: Small Animal Practice 2002, 32:983-995.
44. Tanaka K., Ichihara A. Half-life of proteasomes (multiprotease complexes) in rat liver. Biochemical and Biophysical Research Communications 1989, 159:1309-1315.
45. Vail D.M., MacEwen E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000, 18:781-792.
46. Wang E.W., Kessler B.M., Borodovsky A., Cravatt B.F., Bogyo M., et al. Integration of the ubiquitin-proteasome pathway with a cytosolic oligopeptidase activity. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:9990-9995.
47. Zhao J., Tenev T., Martins L.M., Downward J., Lemoine N.R. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. Journal of Cell Science 2000, 113:4363-4371.